FindAPhD Weekly PhD Newsletter | JOIN NOW FindAPhD Weekly PhD Newsletter | JOIN NOW

University of Oxford, Department of Oncology PhD Projects, Programmes & Scholarships

We have 14 University of Oxford, Department of Oncology PhD Projects, Programmes & Scholarships

Discipline

Discipline

All disciplines

Location

Location

All locations

Institution

Institution

Department of Oncology  University of Oxford

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


We have 14 University of Oxford, Department of Oncology PhD Projects, Programmes & Scholarships

PhD saved successfully

Molecular mechanisms of mitotic DNA synthesis in BRCA2-deficient cells

Aberrant replication causes cells lacking BRCA2 to enter mitosis with under-replicated DNA, which activates a repair mechanism known as mitotic DNA synthesis (MiDAS). Read more

Investigation into the dynamics of DNA damage and repair of cells following FLASH and conventional irradiation

FLASH radiation is a novel radiotherapy technique that shows great potential in improving cancer treatment.1 However, very little is known about the biological mechanisms behind the highly beneficial FLASH effect. Read more

Clinically-motivated and physics-informed deep learning for contouring tumours using multimodal cancer imaging

Contouring tumour volumes is an important early step in the radiotherapy planning process. Several imaging modalities (CT, PET and MRI) are used to guide contouring, but inter-observer variation in contouring tumour volumes can be significant. Read more

Hypermutation as a driving force for cancer: can there be too much of a good thing?

DNA polymerases epsilon (POLE) and delta (POLD1) are essential for DNA replication. As part of this process, these enzymes have 3’-exonuclease proofreading activity, to check that the correct base has been incorporated on the new, growing DNA strand. Read more

Understanding the effects of immunomodulatory therapies on radiation response

Dying cancer cells are thought to be a rich source of tumour antigens and danger signals into the tumour microenvironment. Work from the Olcina lab has found that targeting complement can increase tumour cell death following radiotherapy which may in turn modulate anti-tumour immune responses. Read more

Nucleases and helicases as potential cancer targets

It is clear that the acquired genetic changes (vulnerabilities) in tumours can be exploited to treat cancer, increasingly in a manner tailored to individual patients. Read more

Investigating the role of E3 ubiquitin ligases in cancer pathogenesis

The Ubiquitin Proteasome System (UPS) is a crucial regulator of cell survival in normal conditions and after DNA damage. The function of UPS is dysregulated in cancer, thus providing a large repertoire of targets to exploit for better cancer treatment. Read more

Parallels between the biological response to viral infection and hypoxia

Regions of low oxygen or hypoxia occur in most solid tumours and predict for a poor patient outcome. Cancer cells adapt to hypoxic conditions and become resistant to therapy, therefore finding new strategies to target tumour hypoxia is essential to improve patient care. Read more

Characterisation of DNA-protein crosslink proteolysis repair in response to chemotherapy

DNA-protein crosslinks (DPCs) are under-investigated DNA lesions caused by the covalent attachment of proteins to DNA. DPCs are induced by endogenous aldehydes, chemotherapeutic drugs (such as PARP1 or Topoisomerase inhibitors) and ionising radiation. Read more

Personalised Radionuclide Theranostics for Cancer

The adoption of highly effective anticancer radiopharmaceuticals such as 223Ra, 177Lu[Lu]-PSMA and 177Lu[Lu]-DOTATAE and, in some cases, their companion imaging tracers, into oncologic practise over the last few years has invigorated the field of radiopharmaceutical therapeutics. Read more
  • 1

Filtering Results